Budesonide oral suspension - Shire

Drug Profile

Budesonide oral suspension - Shire

Alternative Names: Oral viscous budesonide; SHP 621

Latest Information Update: 14 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Verus Pharmaceuticals
  • Developer Shire
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eosinophilic oesophagitis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Eosinophilic oesophagitis

Most Recent Events

  • 16 Aug 2017 Shire plans a phase III extension trial for Eosinophilic oesophagitis (In children, In adolescents, In adults) (NCT03245840)
  • 13 Jun 2016 Budesonide oral suspension - Shire receives Breakthrough Therapy status for Eosinophilic oesophagitis (In adolescents, In adults) in USA
  • 01 Apr 2016 Shire initiates the extension phase III ORBIT2 trial for Eosinophilic oesophagitis (In adolescents, In adults) in USA (PO) (NCT02736409)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top